Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05203510 · ClinicalTrials.gov registry record · Phase 4
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
A Phase 4 study of Pulmonary Arterial Hypertension, sponsored by United Therapeutics.
- Active
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 20
- Study locations
NCT05203510 is a Phase 4 study of Pulmonary Arterial Hypertension that is active but no longer recruiting, run by United Therapeutics. The registered enrollment target is 52 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05203510, a Phase 4 study of Pulmonary Arterial Hypertension, is active but no longer recruiting, sponsored by United Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
Conditions Studied
Interventions
- DRUG Parenteral Treprostinil
- DRUG Oral Treprostinil
Study Locations (20)
California
- University of California San Francisco - Fresno - Fresno
- Cedars-Sinai Medical Center - Los Angeles
- University of California Davis Medical Center - Sacramento
- University of California San Francisco Pulmonary, Critical Care, Allergy and Sleep Medicine - San Francisco
Arizona
- Banner University Medical Center (University of Arizona) - Phoenix
- HonorHealth John C. Lincoln Medical Center - Phoenix
Indiana
- Indiana University Health North Hospital - Indianapolis
- Community Health Network - Indianapolis
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Duke University Medical Center - Durham
Connecticut
- Hartford Hospital - Hartford
Florida
- USF - Tampa
Georgia
- Georgia Clinical Research - Austell
Illinois
- Northwestern Memorial Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-10-20 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05203510
The ClinicalTrials.gov registry entry for NCT05203510 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (89% lower). The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Parenteral Treprostinil is the first listed.
NCT05203510 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Arizona, Indiana.
Frequently Asked Questions
What is clinical trial NCT05203510 about?
NCT05203510 is a clinical study titled "A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension". The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
What is the current status of trial NCT05203510?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2022-10-20. Estimated completion is 2028-04-30.
What conditions does trial NCT05203510 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT05203510?
The interventions under investigation include: Parenteral Treprostinil (DRUG), Oral Treprostinil (DRUG).
Who is sponsoring clinical trial NCT05203510?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05203510 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 4
-
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
COMPLETED · Phase 4
-
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
COMPLETED · Phase 4
-
Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
COMPLETED · Phase 4
-
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
COMPLETED · Phase 4
-
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.